3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
3
Phase NA
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Breast Neoplasms
2
Vomiting
1
Uterine Cervical Neoplasms
1
Trigger Finger Disorder
1
Sarcoma, Alveolar Soft Part
1
Renal Insufficiency
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Pain
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nausea
1
Mucositis
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Mast-Cell
1
Leukemia, Hairy Cell
1
Interventions
Carboplatin
195
Cisplatin
117
Paclitaxel
107
Pemetrexed
106
Docetaxel
96
Gemcitabine
89
Radiotherapy
83
Erlotinib Hydrochloride
58
Bevacizumab
55
Etoposide
49
durvalumab
39
pembrolizumab
38
Nivolumab
31
Specimen Handling
30
Magnetic Resonance Spectroscopy
30
Irinotecan
27
Radiosurgery
26
osimertinib
24
Gefitinib
24
Drug Therapy
23
Vinorelbine
22
atezolizumab
20
Topotecan
20
Radiation
16
Cetuximab
16
Taxes
15
Surgical Procedures, Operative
14
Neoadjuvant Therapy
13
Filgrastim
13
Chemotherapy, Adjuvant
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lung Neoplasms
×
Acetaminophen
×
Clear all
NCT06788912
2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled